Hospital
Avita Ontario Hospital
Avita Ontario Hospital was paid $19.73M by Medicaid between Jan 2018 and Dec 2024, across 321 billing codes. Its largest line is 99211, Office or other outpatient visit for the evaluation and management of an established patient, minimal severity — 26% of everything it billed.
33Billing provider infoAVITA ONTARIO HOSPITAL
ONTARIO, OH 44906
ONTARIO, OH 44906
33aNPI1790131050assigned 05/05/2016
33bProvider typeGeneral Acute Care Hospital
28Total paid$19.73M
24GClaims560,027
24DCodes billed321
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#53 of 101
Median peer was paid$22.32M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 35,821 | $1.20M | |
| 2019 | 47,369 | $1.62M | |
| 2020 | 36,132 | $2.02M | |
| 2021 | 46,982 | $2.42M | |
| 2022 | 55,193 | $2.40M | |
| 2023 | 185,583 | $5.42M | |
| 2024incomplete | 152,947 | $4.65M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 26% | 62,023 | 53,688 | $5.05M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 35,011 | 32,264 | $3.34M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 22,596 | 20,181 | $2.29M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.3% | 9,633 | 8,207 | $1.04M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.6% | 9,338 | 8,633 | $708K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.9% | 2,029 | 1,493 | $577K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.3% | 1,859 | 1,509 | $461K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.2% | 6,074 | 5,518 | $433K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 1,613 | 1,270 | $386K |
| 20610 | 1.7% | 3,117 | 2,369 | $336K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 1,447 | 1,195 | $334K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 3,418 | 3,177 | $318K |
309 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 741 | $259K |
| 31231 | 1.3% | 1,015 | $253K | |
| 80053 | Comprehensive metabolic panel | <1% | 20,817 | $196K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,341 | $174K |
| 52000 | <1% | 341 | $161K | |
| 97803 | <1% | 1,960 | $149K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,842 | $148K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,323 | $140K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 919 | $136K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 8,053 | $135K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 564 | $133K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 707 | $133K |
| G0378 | Hospital observation service, per hour | <1% | 2,132 | $132K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 511 | $113K |
| 59025 | Fetal non-stress test | <1% | 798 | $107K |
| 31575 | <1% | 428 | $89K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,312 | $85K |
| 97804 | <1% | 973 | $73K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 426 | $70K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,551 | $64K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 31,058 | $62K |
| 80061 | Lipid panel | <1% | 6,106 | $59K |
| 96130 | <1% | 645 | $58K | |
| 71250 | <1% | 729 | $57K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 306 | $54K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,313 | $50K |
| 36415 | Collection of venous blood by venipuncture | <1% | 36,038 | $47K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 640 | $42K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 580 | $40K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 10,517 | $39K |
| 96131 | <1% | 221 | $38K | |
| 81003 | <1% | 5,182 | $32K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,366 | $29K |
| 86140 | <1% | 3,821 | $28K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,681 | $27K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 191 | $27K |
| 43235 | <1% | 75 | $26K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 96 | $26K |
| 76770 | <1% | 190 | $24K | |
| 92557 | <1% | 465 | $24K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,019 | $24K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 137 | $23K |
| 94060 | <1% | 269 | $22K | |
| 82607 | <1% | 1,597 | $22K | |
| 93971 | <1% | 381 | $20K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 463 | $18K |
| 80069 | <1% | 1,258 | $16K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 741 | $16K |
| 94664 | <1% | 1,014 | $15K | |
| 93017 | <1% | 230 | $14K | |
| 84439 | <1% | 1,083 | $14K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 477 | $14K |
| 20611 | <1% | 75 | $14K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 98 | $14K |
| J3490 | Unclassified drugs | <1% | 1,583 | $14K |
| 85027 | <1% | 2,280 | $14K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 240 | $13K |
| 86850 | <1% | 706 | $13K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,517 | $13K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,294 | $12K |
| 84550 | <1% | 2,047 | $12K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,503 | $11K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 65 | $11K |
| 82728 | <1% | 947 | $10K | |
| 84484 | <1% | 5,560 | $10K | |
| 82570 | <1% | 1,290 | $10K | |
| 72131 | <1% | 132 | $10K | |
| 83540 | <1% | 1,439 | $9K | |
| 51798 | <1% | 1,021 | $9K | |
| 94727 | <1% | 258 | $9K | |
| 83970 | <1% | 406 | $9K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,120 | $9K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 81 | $9K |
| 86900 | <1% | 824 | $8K | |
| 73564 | <1% | 1,168 | $8K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 129 | $8K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,199 | $8K |
| 94729 | <1% | 259 | $8K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,512 | $8K |
| 72110 | <1% | 511 | $8K | |
| 82746 | <1% | 1,327 | $8K | |
| 76830 | Ultrasound, transvaginal | <1% | 270 | $8K |
| 94618 | <1% | 107 | $8K | |
| 73502 | <1% | 664 | $8K | |
| 80076 | <1% | 2,697 | $7K | |
| 86431 | <1% | 390 | $7K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,116 | $7K |
| 83735 | <1% | 4,572 | $7K | |
| 74018 | <1% | 422 | $7K | |
| 97802 | <1% | 108 | $7K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 158 | $7K |
| 81001 | <1% | 10,612 | $7K | |
| 73030 | <1% | 828 | $6K | |
| 83550 | <1% | 1,091 | $6K | |
| 82550 | <1% | 1,090 | $6K | |
| 90686 | <1% | 517 | $6K | |
| 12001 | <1% | 45 | $6K | |
| 87340 | <1% | 560 | $5K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 461 | $5K |
| 92567 | <1% | 671 | $5K | |
| 87150 | <1% | 803 | $5K | |
| 85610 | <1% | 2,951 | $5K | |
| 82565 | <1% | 6,744 | $5K | |
| 92551 | <1% | 101 | $5K | |
| 84702 | <1% | 551 | $5K | |
| 76536 | <1% | 70 | $5K | |
| 86803 | <1% | 656 | $5K | |
| 87070 | <1% | 3,265 | $5K | |
| 85652 | <1% | 2,414 | $5K | |
| 90715 | <1% | 413 | $5K | |
| 83605 | <1% | 3,171 | $5K | |
| 86701 | <1% | 346 | $4K | |
| 82043 | <1% | 757 | $4K | |
| 90648 | <1% | 585 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 450 | $4K |
| 80051 | <1% | 6,327 | $4K | |
| 86038 | <1% | 359 | $4K | |
| 86901 | <1% | 817 | $4K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 839 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,119 | $4K |
| 73130 | <1% | 603 | $4K | |
| 84425 | <1% | 588 | $4K | |
| 73110 | <1% | 553 | $4K | |
| 73630 | <1% | 706 | $4K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 1,348 | $3K |
| 86704 | <1% | 361 | $3K | |
| 82784 | <1% | 476 | $3K | |
| 73562 | <1% | 701 | $3K | |
| 80344 | <1% | 293 | $3K | |
| 84153 | <1% | 373 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,885 | $3K |
| 72100 | <1% | 243 | $3K | |
| 86706 | <1% | 411 | $3K | |
| 84403 | <1% | 270 | $3K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 17 | $3K |
| 82652 | <1% | 396 | $3K | |
| 70486 | <1% | 29 | $3K | |
| 73221 | <1% | 14 | $3K | |
| 84300 | <1% | 681 | $3K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 35 | $3K |
| 93975 | <1% | 31 | $3K | |
| 73610 | <1% | 694 | $3K | |
| 84156 | <1% | 786 | $3K | |
| 72050 | <1% | 104 | $3K | |
| 86708 | <1% | 358 | $3K | |
| 96376 | <1% | 1,351 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 343 | $2K |
| 85018 | <1% | 412 | $2K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 374 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,234 | $2K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,509 | $2K |
| 96137 | <1% | 602 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,471 | $2K |
| 10060 | <1% | 19 | $2K | |
| 72114 | <1% | 57 | $2K | |
| 90670 | <1% | 157 | $2K | |
| 84590 | <1% | 292 | $2K | |
| 84450 | <1% | 513 | $2K | |
| 84446 | <1% | 283 | $2K | |
| 86160 | <1% | 145 | $2K | |
| 85730 | <1% | 1,338 | $2K | |
| 69210 | <1% | 551 | $2K | |
| 72070 | <1% | 85 | $2K | |
| 92526 | <1% | 39 | $2K | |
| 83516 | <1% | 200 | $2K | |
| 31579 | <1% | 12 | $2K | |
| 82947 | <1% | 6,369 | $2K | |
| 0064A | <1% | 63 | $2K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 762 | $2K |
| 84460 | <1% | 523 | $2K | |
| 81025 | <1% | 3,535 | $2K | |
| 83880 | <1% | 723 | $1K | |
| 84520 | <1% | 6,437 | $1K | |
| 80305 | <1% | 537 | $1K | |
| 86255 | <1% | 123 | $1K | |
| 86320 | <1% | 162 | $1K | |
| 90723 | <1% | 452 | $1K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 108 | $1K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 75 | $1K |
| 83690 | <1% | 5,265 | $1K | |
| 83520 | <1% | 209 | $1K | |
| 82948 | <1% | 1,806 | $1K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 12 | $1K |
| 87186 | <1% | 963 | $1K | |
| 84630 | <1% | 68 | $962.24 | |
| 87088 | <1% | 790 | $961.07 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 285 | $941.19 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,408 | $915.99 |
| 84207 | <1% | 117 | $915.76 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 65 | $901.36 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 135 | $815.24 |
| 85651 | <1% | 397 | $802.83 | |
| 86430 | <1% | 134 | $794.71 | |
| 96101 | <1% | 16 | $746.48 | |
| 82164 | <1% | 51 | $704.83 | |
| 90656 | <1% | 60 | $702.87 | |
| 87040 | <1% | 918 | $664.72 | |
| 92552 | <1% | 12 | $637.49 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 82 | $633.33 |
| 82247 | <1% | 146 | $629.45 | |
| 84703 | <1% | 935 | $616.60 | |
| 97116 | <1% | 69 | $609.57 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,117 | $601.04 |
| 90633 | <1% | 75 | $598.93 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 14 | $518.25 |
| 84165 | <1% | 184 | $491.97 | |
| 77080 | <1% | 12 | $489.55 | |
| 93242 | <1% | 14 | $471.32 | |
| 90681 | <1% | 161 | $455.81 | |
| 96136 | <1% | 591 | $453.25 | |
| 82803 | <1% | 302 | $437.60 | |
| 86480 | <1% | 15 | $436.66 | |
| 84145 | <1% | 83 | $436.25 | |
| 85378 | <1% | 1,134 | $419.93 | |
| 86618 | <1% | 55 | $407.80 | |
| 97162 | <1% | 59 | $367.80 | |
| 73080 | <1% | 49 | $362.64 | |
| 87449 | <1% | 117 | $347.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,927 | $288.96 |
| 84100 | <1% | 160 | $266.17 | |
| 82248 | <1% | 84 | $234.79 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,041 | $228.03 |
| 82010 | <1% | 214 | $215.57 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,917 | $209.63 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 448 | $194.72 |
| 86592 | <1% | 25 | $176.89 | |
| 72202 | <1% | 13 | $143.76 | |
| 77073 | <1% | 89 | $141.93 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 211 | $140.39 |
| 86200 | <1% | 61 | $140.32 | |
| 82525 | <1% | 13 | $140.06 | |
| 83525 | <1% | 12 | $138.79 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,739 | $136.50 |
| 87077 | <1% | 144 | $128.88 | |
| 90710 | <1% | 34 | $125.04 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 208 | $124.09 |
| 86308 | <1% | 70 | $114.03 | |
| 85045 | <1% | 42 | $108.95 | |
| 82310 | <1% | 50 | $108.85 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,700 | $108.76 |
| 85014 | <1% | 45 | $101.50 | |
| 90734 | <1% | 12 | $100.00 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 575 | $95.41 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 405 | $94.72 |
| 73590 | <1% | 14 | $92.22 | |
| 84075 | <1% | 53 | $91.43 | |
| 74022 | <1% | 19 | $88.14 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 145 | $79.84 |
| 87210 | <1% | 29 | $75.35 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 250 | $72.80 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,063 | $71.01 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 792 | $70.19 |
| 86780 | <1% | 13 | $66.82 | |
| 85049 | <1% | 12 | $66.23 | |
| 87220 | <1% | 28 | $65.50 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 235 | $61.99 |
| 73100 | <1% | 15 | $59.90 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 12 | $53.54 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 22 | $52.19 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,673 | $49.10 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 376 | $48.99 |
| 84155 | <1% | 30 | $43.14 | |
| 90694 | <1% | 19 | $42.66 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,705 | $42.38 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 825 | $39.22 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 61 | $38.78 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,800 | $37.76 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 176 | $37.56 |
| 73120 | <1% | 13 | $35.94 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 96 | $32.90 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 22 | $32.20 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 32 | $30.53 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,187 | $29.12 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,179 | $27.23 |
| 82747 | <1% | 30 | $26.25 | |
| 87205 | <1% | 100 | $22.07 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 139 | $21.08 |
| 87493 | <1% | 40 | $20.69 | |
| 73140 | <1% | 22 | $13.47 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 58 | $10.65 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 199 | $8.19 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,615 | $6.54 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 75 | $2.25 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 21 | $1.36 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 746 | $0.98 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 59 | $0.85 |
| 91306 | <1% | 63 | $0.60 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 28 | $0.27 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 87 | $0.00 |
| 76937 | 0% | 107 | $0.00 | |
| 92504 | 0% | 152 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 143 | $0.00 |
| 90662 | 0% | 14 | $0.00 | |
| 88313 | 0% | 44 | $0.00 | |
| J1240 | Injection, dimenhydrinate, up to 50 mg | 0% | 33 | $0.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 29 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 31 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 44 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 69 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 39 | $0.00 |
| 94761 | 0% | 273 | $0.00 | |
| 36000 | 0% | 15 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 123 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 55 | $0.00 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 0% | 17 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 84 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 25 | $0.00 |
| A9270 | Non-covered item or service | 0% | 55 | $0.00 |
| 82150 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDRAIME, DONALD (CFO)
Parent organizationAVITA HEALTH SYSTEM
| Provider | Location | Paid |
|---|---|---|
| Galion Community Hospital | Galion, OH | $25.15M |
| Galion Community Hospital | Galion, OH | $80K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.